Silo Pharma Secures European Patent for Preventative PTSD Therapy
Event summary
- Silo Pharma received European Patent No. EP3952852 for its SPC-15 therapy, covering preventative treatment of stress-induced psychiatric disorders.
- The patent protects a novel intranasal approach targeting serotonin 4 (5-HT4) receptors to prevent PTSD before symptom onset.
- Silo holds an exclusive license from Columbia University for global development and commercialization of SPC-15.
The big picture
Silo Pharma's European patent for SPC-15 reinforces its strategy of targeting stress resilience pathways, a shift from traditional PTSD treatments. This aligns with growing industry interest in preventative mental health solutions, particularly for high-risk populations like military personnel and first responders. The company's dual focus on biopharmaceutical innovation and AI-driven research platforms positions it uniquely in the converging fields of neuroscience and digital health.
What we're watching
- Market Expansion
- Whether Silo can leverage this European patent to accelerate clinical development and partnerships in key markets.
- Competitive Positioning
- How this preventative approach differentiates SPC-15 from existing PTSD treatments focused on symptom management.
- Regulatory Momentum
- The pace at which Silo secures additional patents in other major global markets to strengthen its IP moat.